Clinical trial
The Evaluation of the Efficacy and Safety of Switching to Once-daily IDegLira in Patients With Type 2 Diabetes Receiving Premixed Insulin Therapy, a Multi-center, Randomized Control Trial
NCT06408532 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Evaluation of the Efficacy and Safety of Switching to Once-daily IDegLira in Patients With Type 2 Diabetes Receiving Premixed Insulin Therapy, a Multi-center, Randomized Control Trial
- Lead sponsor
- Peking University People's Hospital
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- April 30, 2024
- Completion date
- February 28, 2025
- Enrollment
- 256 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.